Clinical trial
Rhenium Re 188 P2045 in Patients With Lung Cancer Who Have Received or Refused…
NCT00100256 · Andarix Pharmaceuticals, Industry · Unknown status
Key facts
| NCT number | NCT00100256 |
|---|---|
| Title | Rhenium Re 188 P2045 in Patients With Lung Cancer Who Have Received or Refused to Receive Prior Chemotherapy |
| Official title | Open Label Study of Single Dose Rhenium Re 188 P2045 in Patients With Lung Cancer Who Have Received or Refused to Receive Prior Chemotherapy |
| Lead sponsor | Andarix Pharmaceuticals, Industry |
| Status | Unknown status |
| Phase | Phase 1/Phase 2 |
| Study type | Interventional |
| Conditions | Lung Neoplasms, Carcinoma, Non-Small-Cell Lung, Small Cell, Neoplasm Recurrence, Local |
| Intervention type | Drug |
| Interventions | Rhenium (Re 188 P2045, BAY86-5284) |
| Enrollment | 60 |
| Start date | Jan 1, 2004 |
| Primary completion | Jun 20, 2009 |
| Completion | Apr 20, 2025 |
| First posted | Dec 28, 2004 |
| Last update posted | Nov 7, 2022 |
| Countries | United States |
At a glance
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: